抄録
We investigated whether a constant plasma concentration could be obtained by the individualized administration of low-dose, prolonged-infusional etoposide. Etoposide was infused for 14 days at 40 mg/m2/day initially in patients with inoperable non-small-cell lung cancer. The infusion rate was modified based upon the etoposide concentration at 24 h following the initiation of the infusion (C24) to achieve a target concentration of 1.5 μg/ml. We postulated that severe toxicities could be avoided by maintaining the steady-state concentration at less than 2 μg/ml, while antitumor activity could be expected if the steady-state concentration was maintained at more than 1 μg/ml. In a total of 21 courses in 12 patients, the mean etoposide dose was 35 ± 6 mg/m2 daily. The C24 was 1.8 ± 0.4 μg/ml and ranged from 1.1 to 2.9 μg/ml. Following dose modification, the mean concentration from 96 to 336 h (C(mean)) was 1.6 ± 0.2 μg/ml and ranged from 1.2 to 2.0 μg/ml. The toxicities were well-tolerated except for one patient with WHO grade 4 leukopenia and neutropenia who developed infectious complications. There were no treatment-related deaths. Following dose modification, the inter-patient variability was decreased successfully. Although this pharmacologically-guided method needs to be validated using more patients, it could be used for therapeutic drug monitoring.
| 本文言語 | 英語 |
|---|---|
| ページ(範囲) | 200-205 |
| ページ数 | 6 |
| ジャーナル | Japanese Journal of Cancer Research |
| 巻 | 87 |
| 号 | 2 |
| DOI | |
| 出版ステータス | 出版済み - 02-1996 |
| 外部発表 | はい |
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
-
SDG 3 すべての人に健康と福祉を
All Science Journal Classification (ASJC) codes
- 腫瘍学
- 癌研究
フィンガープリント
「Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。引用スタイル
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver